The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6.
about
A model for cofactor use during HIV-1 reverse transcription and nuclear entryDiscovery of Novel Small-Molecule HIV-1 Replication Inhibitors That Stabilize Capsid ComplexesStructural basis for nuclear import of splicing factors by human Transportin 3Structural basis of HIV-1 capsid recognition by PF74 and CPSF6.HIV-1 capsids bind and exploit the kinesin-1 adaptor FEZ1 for inward movement to the nucleus.Phosphorylation of the HIV-1 capsid by MELK triggers uncoating to promote viral cDNA synthesis.MxB binds to the HIV-1 core and prevents the uncoating process of HIV-1The HIV-1 integrase mutant R263A/K264A is 2-fold defective for TRN-SR2 binding and viral nuclear import.BI-2 destabilizes HIV-1 cores during infection and Prevents Binding of CPSF6 to the HIV-1 CapsidNucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 capsid protein to mediate lentiviral infectivity.A cyclophilin homology domain-independent role for Nup358 in HIV-1 infection.SJP-L-5, a novel small-molecule compound, inhibits HIV-1 infection by blocking viral DNA nuclear entry.HIV-1 Capsid Inhibitors as Antiretroviral AgentsSUN2 Overexpression Deforms Nuclear Shape and Inhibits HIV.HIV-1 capsid is involved in post-nuclear entry stepsThe Cleavage and Polyadenylation Specificity Factor 6 (CPSF6) Subunit of the Capsid-recruited Pre-messenger RNA Cleavage Factor I (CFIm) Complex Mediates HIV-1 Integration into Genes.Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly.Viral subversion of the nuclear pore complex.Quantitative analysis of the time-course of viral DNA forms during the HIV-1 life cycleNuclear import of APOBEC3F-labeled HIV-1 preintegration complexes.HIV-1 uncoating: connection to nuclear entry and regulation by host proteins.Contribution of PDZD8 to stabilization of the human immunodeficiency virus type 1 capsid.Viral and cellular requirements for the nuclear entry of retroviral preintegration nucleoprotein complexes.Putting an 'End' to HIV mRNAs: capping and polyadenylation as potential therapeutic targets.The small-molecule 3G11 inhibits HIV-1 reverse transcription.Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsidCapsid-Dependent Host Factors in HIV-1 Infection.Distinct functions of diaphanous-related formins regulate HIV-1 uncoating and transport.Roles of Capsid-Interacting Host Factors in Multimodal Inhibition of HIV-1 by PF74.HIV-1 Capsid Stabilization Assay.In vivo functions of CPSF6 for HIV-1 as revealed by HIV-1 capsid evolution in HLA-B27-positive subjects.Keeping your armour intact: how HIV-1 evades detection by the innate immune system: HIV-1 capsid controls detection of reverse transcription products by the cytosolic DNA sensor cGAS.Human cytosolic extracts stabilize the HIV-1 coreInteraction of transportin-SR2 with Ras-related nuclear protein (Ran) GTPaseCellular and molecular mechanisms of HIV-1 integration targeting.Prospects for Foamy Viral Vector Anti-HIV Gene Therapy.Truncated CPSF6 forms higher order complexes that bind and disrupt HIV-1 capsid.Nup153 Unlocks the Nuclear Pore Complex for HIV-1 Nuclear Translocation in Non-dividing CellsNuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2
P2860
Q26859218-EEF34CFD-FECF-4F03-9D22-DBD86A102D4CQ27678859-C07CC126-9330-41B6-88B4-D1F0FC56CB02Q27681422-28A4B2D1-07A9-4234-8726-D796F3A9FBFEQ30301100-F48CDD2E-9D0C-45D7-B4E6-9368A86C574AQ30634144-DDE980C5-35B7-4C4A-94C9-865C988A2879Q33880794-A9B4BA24-5517-4711-A002-D5B2D1BC358BQ34091405-8F49A402-DD17-4694-9833-29C0DE633B20Q34139212-97002B83-2174-4C32-ADFA-66DDEB37CD2DQ34738657-7D0EE1B1-13CA-4DE8-AEEC-4785123789C8Q35018068-5FCFDA2B-AFCC-4559-A323-BC82CC57F9AAQ35105663-49FF70AC-19A5-47D2-A036-E7E4A51A50F8Q35859394-0F271A98-3F70-4A60-9895-5197A00FB753Q36672006-88AB371E-8A51-4376-9DEC-EAF46A89DFD4Q36736438-3693882F-31D0-45A9-B21C-D79DB21B85CAQ36828934-A796FE6B-95EC-450F-9213-F07C312E0AB6Q36941113-65827CAD-A877-4E47-AF9F-C5EEB50BC2BCQ36950909-976EBB92-0815-4898-A28C-ECBCE38550A8Q37142582-6E803684-86DC-4DE9-BADE-BB978A08CFE2Q37153500-5618992C-AF94-47E2-8CE8-E4A8A82BC085Q37377405-E72A28D5-0F5B-4362-85E2-3FCA6406093EQ37705207-3615A4D3-3C00-4584-96CB-C52AFA5BF977Q37714016-3496DEF6-3C79-4A0C-9764-3984D6707444Q38150610-14EB6E70-D99E-4356-88B0-43DDE92B2390Q38170575-E0958A1B-33BA-4E48-B85B-5868B84E2D32Q38740847-E1C7CCB8-945F-4D50-8C77-AA33CA06A92FQ38927692-3FAD87FF-1AD1-4358-ABD2-A914233B0FC3Q39320682-0AE0E210-0F55-4250-80EC-585915A0273BQ40100619-232472D7-A9A2-48CB-8205-DA8260FC5EDBQ40715418-9587E3DE-EBB5-4BE6-8979-A2CF2A3AD9EEQ40852784-7F2EC859-28B4-4B5A-9EC6-A886DD650761Q41863178-B4229C1A-A6D4-48FA-9646-008249EC66DEQ41950656-99EA0AC2-A992-4D90-B9A3-9997C85EECBCQ42281556-941DF69F-4214-498A-A5F8-3564077293FFQ42282078-2E27D2E7-F0AA-4829-9F39-572877DCF2F2Q50126703-4A228F39-6DC8-4346-82D7-839E53B25998Q50878341-17B089D1-88BC-4E9D-89C6-834EC23AAACDQ52324506-68D9F340-66B5-4FD3-BFE0-7D70468A8532Q56342048-379B6FAD-26E4-4D4F-87CD-F434BF7FE007Q56530177-25F4BE21-5150-4BBA-9FEA-1721A03F9444
P2860
The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6.
@en
type
label
The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6.
@en
prefLabel
The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6.
@en
P2093
P2860
P50
P356
P1433
P1476
The ability of TNPO3-depleted cells to inhibit HIV-1 infection requires CPSF6
@en
P2093
Felipe Diaz-Griffero
Natalia Reszka
Thomas Fricke
Tommy E White
William J Bosche
P2860
P2888
P356
10.1186/1742-4690-10-46
P577
2013-04-26T00:00:00Z
P5875
P6179
1039469087